跳至主要内容
临床试验/NCT04670887
NCT04670887尚未招募不适用

A Prospective Multicenter Trial Comparing Surgery Versus Active Surveillance In Patients With Bosniak 3 Renal Cystic Masses, A NoRenCa And FinnKidney Study

Helsinki University Central Hospital0 个研究点目标入组 200 人开始时间: 2021年3月15日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
200
主要终点
Malignancy rate in surgical pathology

研究概览

简要总结

The incidence of renal cysts is rising due to increased abdominal imaging. Renal complicated cysts have been traditionally classified according to the Bosniak classification, which distinguishes cystic masses by specific features of walls and septa. The categories I and II are benign and class IIF most probably benign but needs a short radiological follow-up. Categories III and IV have been traditionally operated due to the increased risk of renal cell carcinoma. However, recently published studies show that approximately 50% of the operated Bosniak III cystic masses are benign, which means that half of the cases are overtreated by surgery. It has also been shown that surgical pathology of stable Bosniak IIF cysts is malignant in less than 1%, while the cysts, which are upgraded to higher Bosniak classes will show malignant surgical pathology in 85%. So far, there is lack of prospective data on active surveillance in Bosniak III cystic masses.

The aim of the study is to compare active surveillance and surgery in patients with Bosniak III renal cystic masses. Patients will be randomized in active surveillance or immediate surgical excision of a cystic mass. In the active surveillance group, patients are followed according to the study protocol for 10 years and treated with delayed surgery if the cystic mass upgrades into Bosniak IV/solid, becomes symptomatic or grows over a preclassified threshold. The primary objective is to compare surgical pathology between patients treated with immediate surgery versus delayed surgery.

According to recent retrospective data, active surveillance of Bosniak III cystic masses is reasonable and oncologically safe. Therefore a prospective randomized controlled trial is needed to get high level evidence to support a change in the treatment strategy. The study may significantly reduce unnecessary operations performed in patients with Bosniak III cystic masses.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • A sporadic single CM of Bosniak 3 according to the Bosniak Classification v.2019 is diagnosed with CT or MRI
  • Maximal diameter of CM 10-70 mm
  • Age ≥50 years
  • ECOG performance status <2
  • Life expectancy ≥5 years
  • Patient is fit to undergo surgery and AS.
  • Patient understands a national language or English
  • Signed informed consent

排除标准

  • Genetic syndromes associated with RCC
  • Previously or simultaneously diagnosed and pathologically verified RCC
  • Previously or simultaneously radiographically identified solid mass or CM of Bosniak 3/4 with diameter ≥10mm
  • The target CM of Bosniak 3 has progressed in sequential imaging from Bosniak 1-2F
  • Presence of radiographic findings which are suspect for nodal or distant metastatic disease
  • Symptomatic CM
  • Kidney insufficiency (GFR<55 ml/min/1,73m2)
  • Patients who have contraindications for both CT and MRI imaging. . Anatomically solitary kidney

结局指标

主要结局

Malignancy rate in surgical pathology

时间窗: From date of randomization until the date of surgery, assessed up to 120 months

次要结局

  • Cancer specific survival(From date of randomization until the date of death due to renal cancer, assessed up to 120 months)
  • Overall survival(From date of randomization until the date of death from any cause, assessed up to 120 months)
  • Progression-free survival(From date of randomization until the date of first documented progression, assessed up to 120 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Harry Nisén

Adjunct professor

Helsinki University Central Hospital

相似试验